HOUSTON, Dec. 14, 2007 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals Inc. (Nasdaq:ENCY) today announced guidance for sales of THELIN(r)(1) (sitaxentan sodium(2)) 100 mg tablets for 2007 and 2008. THELIN is the first selective endothelin A receptor antagonist, and the first once-daily oral treatment available for patients with Pulmonary Arterial Hypertension (PAH) in the European Union (EU).
